Holen Sie sich die Stockscreener-App
75.25
1.06%
-0.81
Schlusskurs vom Vortag:
$76.06
Offen:
$77.55
24-Stunden-Volumen:
2.82M
Relative Volume:
1.12
Marktkapitalisierung:
$14.42B
Einnahmen:
$353.78M
Nettoeinkommen (Verlust:
$-805.69M
KGV:
-17.97
EPS:
-4.1869
Netto-Cashflow:
$-597.61M
1W Leistung:
+10.58%
1M Leistung:
-4.88%
6M Leistung:
+49.36%
1J Leistung:
+138.43%
1-Tages-Spanne:
$72.82
$77.78
1-Wochen-Bereich:
$67.82
$84.94
52-Wochen-Spanne:
$28.32
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
75.25 | 14.58B | 353.78M | -805.69M | -597.61M | -4.1869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-12-11 | Eingeleitet | Bernstein | Outperform |
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia - Yahoo Finance
BridgeBio Pharma, DoorDash, Nvidia, Rio Tinto: What brokers said this week - Proactive financial news
Is BridgeBio Pharma Inc. a speculative investment2025 Top Decliners & AI Driven Stock Movement Reports - mfd.ru
BridgeBio Pharma (NASDAQ:BBIO) Given New $83.00 Price Target at Oppenheimer - MarketBeat
BBIO: Oppenheimer Raises Price Target for BridgeBio Pharma | BBIO Stock News - GuruFocus
BridgeBio's Impressive Phase 3 Infigratinib Data Adds Competitive Pressure to BioMarin's Voxzogo - Morningstar
Oppenheimer Adjusts BridgeBio Pharma Price Target to $83 From $81, Maintains Outperform Rating - marketscreener.com
BBIO: Wells Fargo Raises Price Target to $98 While Maintaining 'Overweight' Rating | BBIO Stock News - GuruFocus
Wells Fargo & Company Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win - Clinical Trials Arena
BridgeBio Pharma stock hits all-time high at 84.51 USD By Investing.com - Investing.com South Africa
Jefferies Maintains Buy on BBIO BridgeBio Pharma, Inc. Feb 2026 - Meyka
Allspring Growth Fund Q4 2025 Fund Performers And Detractors - Seeking Alpha
BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share - Citeline News & Insights
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares - MarketBeat
Dwarfism golden gate? Bridgebio’s infigratinib phase III hits - BioWorld MedTech
BridgeBio Announces Positive Phase 3 Achondroplasia Trial Results - TipRanks
Dwarfism meds 'miraculously' took kids who started at a low growth baseline to typical height velocity: BridgeBio Pharma CEO - Fox Business
BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug - Proactive financial news
BridgeBio reports positive phase 3 topline results for oral infigratinib - marketscreener.com
BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing - MedCity News
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week HighHere's What Happened - MarketBeat
BridgeBio's oral drug improves growth in children with dwarfism in late-stage study - marketscreener.com
BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? - Stocktwits
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Bitget
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga
BridgeBio (BBIO) Surges on Positive Phase 3 Results for Infigrat - GuruFocus
BridgeBio gains on phase 3 dwarfism data - pharmaphorum
Positive Phase III top-line results for BridgeBio’s oral infigratinib - The Pharma Letter
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
BridgeBio Pharma stock price target raised to $89 at Raymond James on positive trial data - Investing.com Canada
BridgeBio Pharma stock hits all-time high at 84.51 USD - Investing.com
BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia - MarketBeat
BridgeBio posts trial win for dwarfism drug (BBIO:NASDAQ) - Seeking Alpha
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data By Investing.com - Investing.com Canada
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - The Manila Times
BridgeBio stock jumps after positive Phase 3 results for achondroplasia drug - Investing.com Canada
BridgeBio Pharma Reports Positive Topline Results from PROPEL 3 Study of Oral Infigratinib in Children with Achondroplasia - Quiver Quantitative
BBIO: Oral infigratinib delivers significant growth and proportionality benefits in achondroplasia - TradingView
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
How BridgeBio Pharma Inc. stock reacts to global recession fearsJuly 2025 Earnings & Fast Gaining Stock Reports - mfd.ru
BridgeBio Pharma (BBIO) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Why (BBIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
What is BridgeBio Pharma Inc.’s book value per shareWeekly Profit Recap & Verified Chart Pattern Trade Signals - mfd.ru
Candriam S.C.A. Invests $7.74 Million in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma supports LGMD Family Guide distribution at conference - Traders Union
Targets Report: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARJuly 2025 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Buy the Dip on This Biotech Stock After Recent Fall - Finviz
BridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bridgebio Pharma Inc-Aktie (BBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Feb 11 '26 |
Sale |
71.78 |
40,000 |
2,871,087 |
675,686 |
| Kumar Neil | Chief Executive Officer |
Jan 09 '26 |
Sale |
77.11 |
40,000 |
3,084,313 |
715,686 |
| Kumar Neil | Chief Executive Officer |
Jan 08 '26 |
Sale |
73.97 |
40,000 |
2,958,855 |
735,686 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):